acenocoumarol has been researched along with Inflammation* in 4 studies
1 trial(s) available for acenocoumarol and Inflammation
Article | Year |
---|---|
Acenocoumarol decreases tissue factor-dependent coagulation during systemic inflammation in humans.
Coumarin derivatives are still widely used for prophylaxis of thromboembolic events and therefore represent important comparator substances for new anticoagulants. Measurement of the efficacy of such novel compounds in a human coagulation model with adequate biomarkers could be useful for early-phase clinical drug development. To evaluate the applicability of a well-established model of tissue factor-dependent coagulation for defining anticoagulant potency, we investigated the effects of acenocoumarol in experimental human endotoxemia.. In a randomized, controlled, 2-by-2 factorial design, healthy volunteers received an infusion of 2 ng/kg endotoxin or placebo after 18 days of pretreatment with acenocoumarol or placebo. Prothrombin fragment 1+2 (F(1+2)), soluble fibrin, and D-dimer were used as markers of thrombin and fibrin formation.. As expected, pretreatment with acenocoumarol decreased vitamin K-dependent coagulation factors, but it also decreased spontaneous thrombin formation. Acenocoumarol inhibited endotoxin-induced thrombin generation as measured by F(1+2) levels: endotoxin infusion increased F(1+2) levels 8-fold-from 0.5 to 4.1 nmol/L-in the placebo group, whereas peak F(1+2) levels reached only 1.0 nmol/L in subjects after acenocoumarol pretreatment. This inhibition was also reflected in decreased formation of soluble fibrin and decreased D-dimer levels, showing that depletion of endogenous coagulation factors limits the propagation of nonovert disseminated intravascular coagulation.. Human endotoxemia is a suitable tool for measurement of the efficacy of oral anticoagulants and therefore may become a valuable addition for expeditious pharmacodynamic characterization of lead compounds with anticoagulant potency. Topics: Acenocoumarol; Adult; Analysis of Variance; Anticoagulants; Biomarkers; Blood Coagulation Tests; Confidence Intervals; Dimerization; Double-Blind Method; Endotoxemia; Factor VIIa; Fibrin Fibrinogen Degradation Products; Humans; Inflammation; Infusions, Intravenous; Lipopolysaccharides; Male; Peptide Fragments; Pilot Projects; Platelet Count; Prothrombin; Solubility; Statistics, Nonparametric; Thromboplastin | 2002 |
3 other study(ies) available for acenocoumarol and Inflammation
Article | Year |
---|---|
Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
This protocol describes microsphere-based protease assays for use in flow cytometry and high-throughput screening. This platform measures a loss of fluorescence from the surface of a microsphere due to the cleavage of an attached fluorescent protease substrate by a suitable protease enzyme. The assay format can be adapted to any site or protein-specific protease of interest and results can be measured in both real time and as endpoint fluorescence assays on a flow cytometer. Endpoint assays are easily adapted to microplate format for flow cytometry high-throughput analysis and inhibitor screening. Topics: Animals; Biotinylation; Flow Cytometry; Fluorescence Resonance Energy Transfer; Green Fluorescent Proteins; High-Throughput Screening Assays; Humans; Inflammation; Kinetics; Microspheres; Peptide Hydrolases; Peptides; Reproducibility of Results; Temperature | 2010 |
No effect of acenocoumarol therapy on levels of endothelial activation markers in sickle cell disease.
Sickle cell patients are characterized by a chronic inflammatory and hypercoagulable state, depicted by elevated levels of pro-inflammatory cytokines, endothelial adhesion molecules, and elevated markers of thrombin generation. We set out to determine whether anticoagulation with a coumadin derivative reduces inflammation in sickle cell disease. Therefore, serum levels of NFkappaB-regulated endothelial adhesion molecule soluble vascular cell adhesion molecule-1 and serum levels of non-NFkappaB-dependent markers of endothelial activation (soluble cellular fibronectin and von Willebrand factor antigen) were compared during treatment with acenocoumarol (INR 1.6-2.0) and placebo. No effect on circulating levels of the measured parameters was observed during treatment with acenocoumarol as compared to placebo. In the targeted INR range, anticoagulation of sickle cell patients with acenocoumarol does not seem to reduce endothelial activation. Topics: Acenocoumarol; Adult; Anemia, Sickle Cell; Anticoagulants; Biomarkers; Endothelium, Vascular; Female; Fibronectins; Humans; Inflammation; Male; Middle Aged; NF-kappa B; Peptide Fragments; Prothrombin; Solubility; Thrombophilia; Vascular Cell Adhesion Molecule-1; von Willebrand Factor | 2002 |
[Submucous hematoma of the cecum under anticoagulant therapy].
A patient developed an intramural hematoma of cecum as a result of indirect anticoagulant treatment. The case is remarkable with respect to the symptomatology and the very restricted extension of the lesion, these features probably resulting from a process of secondary infection. Topics: Acenocoumarol; Bacterial Infections; Cecal Diseases; Gastrointestinal Hemorrhage; Hematoma; Humans; Inflammation; Intestinal Mucosa; Male; Middle Aged | 1986 |